

A CMS Medicare Administrative Contractor
<https://www.NGSMedicare.com>

Voting Questions

For each voting question, please use the following scale identifying your level of confidence - with a score of 1 being low or no confidence and 5 representing high confidence

1- 2- 3- 4- 5

Low confidence Intermediate High confidence

Answers 1-5

1. How confident are you that there is adequate published evidence that the use of KidneyIntelX test improves health outcomes in patients with type 2 diabetes and early stage chronic kidney disease (stages 1-3b)?
2. How confident are you that there is adequate published evidence that KidneyIntelX test accurately predicts the risks of early stage kidney disease progression?
3. If at least intermediate confidence (≥ 3) is noted in question #1 or #2, how confident are you that there is sufficient published evidence that use of Kidney IntelX test to recommend guidelines for proper use?
4. How confident are you that there is adequate published evidence that KidneyIntelX test is an integral component to aid in the medical management of CKD in Medicare beneficiaries?
5. How confident are you that this test offers more clinical importance than albuminuria and eGFR to clinicians in making treatment decisions?
6. How confident are you that based on the Clinical Utility of KidneyIntelX on Patients with Early-stage Diabetic Kidney Disease: A Real-World Evidence Study, KidneyIntelX has resulted in changes in clinical management by clinicians?
7. How confident are you that there is adequate published evidence that KidneyIntelX will improve prediction of near term kidney disease progression and outcomes in patients with T2D and Diabetic Kidney disease?
8. How confident are you that further randomized controlled trials are not necessary to evaluate the efficacy of KidneyIntelX and to identify reduced KidneyIntelX risk scores as a result of initial management?
9. How confident are you that there is adequate published evidence that KidneyIntelX helps decrease socioeconomic disparities in patient groups due to lack of accurate tools to assess those at greatest risk for CKD progression?
10. How confident are you that there is adequately published evidence that the KidneyIntelX test is generalizable to the Medicare patient population?

11. How confident are you that the evidence regarding the use of the KidneyIntelX test changes clinical best practice and management of the Medicare patient population with T2D and Diabetic Kidney disease for CKD progression?
12. How confident are you that the evidence regarding the use of the KidneyIntelX test improves clinical decision making and clinical outcomes of the Medicare patient population with T2D and Diabetic Kidney disease for CKD progression?